1	PHILIP J. GRAVES (SBN 153441)		
2	philipg@hbsslaw.com HAGENS BERMAN SOBOL SHAPIRO LLP		
3	301 North Lake Avenue, Suite 203 Pasadena, CA 91101		
4	301 North Lake Avenue, Suite 203 Pasadena, CA 91101 Telephone: (213) 330-7150 Facsimile: (213) 330-7152		
5	BARBARA MAHONEY (pro hac vice pending) barbaram@hbsslaw.com		
6	HAGENS BERMAN SOBOL SHAPIRO LLP 1918 8th Avenue, Suite 3300		
7	Seattle, WA 98101		
8	Telephone: (206) 623-7292 Facsimile: (206) 623-0594		
9	Attorneys for Plaintiff FEMTO-SEC TECH, INC.		
10			
11	UNITED STATES DISTRICT COURT		
12	CENTRAL DISTRICT OF CALIFORNIA		
13	SOUTHERN DIVISION		
14	FEMTO-SEC TECH, INC., a California	No. 8:15-cv-1689	
15	Corporation, Plaintiff,	COMPLAINT FOR PATENT	
16		INFRINGEMENT AND	
17	V.	DEMAND FOR JURY TRIAL	
18	LENSAR, INC., a Delaware Corporation,		
19	Defendant.		
20			
21			
22			
23			
24			
25			
26	I and the second		
27			
27 28			

Plaintiff Femto-Sec Tech, Inc. ("Femto-Sec"), by and through its undersigned attorneys, pleads as follows:

I. PARTIES

- 1. Femto-Sec is a corporation organized and existing under the laws of the State of California having its principal place of business in Aliso Viejo, California.
- 2. LensAR, Inc. ("LensAR") is a corporation organized and existing under the laws of the State of Delaware, having its headquarters in Orlando, Florida.

II. JURISDICTION AND VENUE

- 3. This Court has subject matter jurisdiction for this action pursuant to 28 U.S.C. §§ 1331 and 1338.
- 4. On information and belief, this Court has personal jurisdiction over LensAR for the reasons, among others, that (i) LensAR transacts business by selling infringing product in California, and (ii) LensAR maintains an agent for service of process in Sanger, California.
- 5. Venue is proper in this District because LensAR resides in this District within the meaning of 28 U.S.C. §§ 1391 and 1400(b).

III. FACTUAL ALLEGATIONS

A. Dr. Neev

- 6. Dr. Joseph Neev, President of Femto-Sec, is a physicist and an inventor of revolutionary applications of lasers in the ophthalmic, dermatological, dental and cardiovascular fields.
- 7. Dr. Neev's career in advancing the use of laser technology to optimize surgical applications began in the late 1980s. His contributions to augment the use of lasers in medical and other applications is well-recognized in the industry, and can be seen through his numerous publications and his affiliation with reputable institutions such as Lawrence Livermore National Laboratory ("Livermore"), the University of California at Irvine ("UCI"), the Beckman Laser Institute, the University of California

- 8. In the mid and late 1990s, Dr. Neev worked as an assistant professor of surgery at the Beckman Laser Institute and Medical Clinic, which was part of the Department of Surgery at UCI. At the time, Dr. Neev worked with other University of California scientists at Livermore on research and development projects relating to ultra-short pulse lasers. Livermore, which was managed by the University of California at the time, is a federally funded research laboratory, entrusted with strengthening the United States' security through the development and application of world-class science and technology.
- 9. Dr. Neev and his collaborators at Livermore developed foundational technology relating to ultra-short pulse lasers with various applications. The Regents of the University of California ("The Regents") applied for and received various patents relating to this foundational technology. Among these patents is U.S. Patent Nos. 5,720,894 (the "'894 Patent"), entitled "Ultrashort Pulse High Repetition Rate Laser System for Biological Tissue Processing," which was issued by the U.S. Patent and Trademark Office on February 24, 1998. Dr. Neev is a named inventor of the '894 patent.
- 10. Following his departure from UCI, Dr. Neev continued his research concerning medical applications of laser technology. Dr. Neev's subsequent work has resulted in the issuance of 15 U.S. Patents covering various laser and light-based biomedical applications, including U.S. Patent No. 6,482,199.

B. The Femto-LLNS License

- 11. Dr. Neev founded Femto-Sec in or about 2007. Femto-Sec is engaged in research and development in the field of ultra-short pulse lasers for medical, ophthalmic, dental, and industrial applications.
- 12. In 2007, Femto-Sec invested significant funds to acquire an exclusive field-of-use license to a group of patents relating to, among other things, femtosecond lasers. As of August 29, 2007, Femto-Sec and The Regents, on information and belief at that time the manager of Livermore, entered into a Limited Exclusive Patent License Agreement for Short-Pulse Laser Technology ("the Femto-LLNS License"). Femto-Sec paid to license patents based on technology developed by Dr. Neev as well as on technology developed by Dr. Neev's former colleagues at Livermore.
- 13. Under the Femto-LLNS License, Femto-Sec was granted an exclusive royalty-bearing license under five patents related to ultra-short pulse laser technology within a field of use comprising medical applications for humans and animals, including medical devices and cosmetic applications, and biological treatments for plants. One of those patents was the '894 Patent.

C. The LENSAR® Laser System

- 14. LensAR markets and sells the LENSAR® Laser System in the United States.
- 15. The LENSAR® Laser System is an ophthalmic surgical laser intended for laser in anterior capsulotomy and laser phacofragmentation in cataract surgery. It has at least the following indicated uses:
 - Anterior capsulotomy and laser phacofragmentation;
 - Removal of the crystalline lens;
 - Creation of full and partial thickness single plane and multi-plane cuts/incisions in the cornea.

- 16. On information and belief, the LENSAR® Laser System is used to selectively ablate and/or modify eye tissue.
- 17. On information and belief, the LENSAR® Laser System operates with a pulse duration of 1500 femtoseconds or less.
- 18. On information and belief, the LENSAR® Laser System operates with a pulse repetition rate of 15 kilohertz.
- 19. On information and belief, when the LENSAR® Laser System is used for an indicated use, the pulsed laser beams are directed and focused to specific locations on and in a patient's eye.
- 20. On information and belief, when the LENSAR® Laser System is used for an indicated use, each pulsed beam forms a plasma at least in part as a result of absorption of the beam's energy by eye tissue.
- 21. On information and belief, when the LENSAR® Laser System is used for an indicated use, the plasma generated by the interaction of a beam and the eye tissue is allowed to decay.
- 22. On information and belief, when the LENSAR® Laser System is used for an indicated use, the platform operates such that there is substantially no transfer of thermal or mechanical energy into and substantially no collateral damage to the surrounding tissue.

COUNT I

INFRINGEMENT OF THE '894 PATENT (Against LensAR)

- 23. Femto-Sec restates and incorporates by reference its previous allegations above, as if fully set forth herein.
- 24. LensAR has infringed and continues to infringe one or more claims of the '894 Patent by making, using, selling or offering to sell in the United States and/or by importing into the United States the LENSAR® Laser System.

- 25. LensAR does not currently have nor has it ever had a license under the '894 Patent.
- 26. Femto-Sec has sustained significant damages as a direct and proximate result of LensAR's infringement of the '894 Patent.
- 27. Femto-Sec will suffer and is suffering irreparable harm from LensAR's infringement of the '894 Patent. Femto-Sec is entitled to an injunction against LensAR's continuing infringement of the '894 Patent. Unless enjoined, LensAR will continue their infringing conduct.
- 28. LensAR's infringement of the '894 Patent is exceptional and entitles Femto-Sec to attorneys' fees and costs incurred in prosecuting this action.

RELIEF REQUESTED

WHEREFORE, Femto-Sec prays that the Court enter judgment as follows:

- A. That LensAR has infringed and continues to infringe the '894 Patent and that the '894 Patent is not invalid and is enforceable;
- B. Awarding Femto-Sec damages adequate to compensate it for LensAR's infringement of the '894 Patent, in an amount to be determined at trial, but in no event less than a reasonable royalty for the use made of the claimed inventions by them;
- C. Awarding a preliminary and permanent injunction restraining and enjoining LensAR, and their officers, agents, servants, employees, attorneys, and any persons in active concert or participation with them who receive actual notice of the order by personal service or otherwise, from any further manufacture, use, sales, offers to sell, or importations of any and all of the products and services identified above;
 - D. Trebling all damages awarded to Femto-Sec under the '894 Patent;
- E. Finding this case exceptional and awarding to Femto-Sec its reasonable attorneys' fees incurred in prosecuting its claims for patent infringement;
 - F. Costs and interest;
 - G. Such other relief as the Court determines to be just and proper.

1		
2	DATED: October 20, 2015	HAGENS BERMAN SOBOL SHAPIRO LLP
3		By: /s/ Philip Graves
4		Philip Graves
5		philipg@hbsslaw.com 301 N. Lake Ave #203
6		Pasadena, CA 91101
7		Telephone: (213) 330-7147
8		Barbara Mahoney (pro hac vice)
9		barbaram@hbsslaw.com HAGENS BERMAN SOBOL SHAPIRO LLP
10		1918 8 th Avenue, Suite 3300
11		Seattle, WA 98101 Telephone: (206) 623-7292
12		Facsimile: (206) 623-0594
13		Attorneys for Plaintiff
14		Attorneys for Plaintiff FEMTO-SEC TECH, INC
15		
16		
17		
18		
19		
20		
21		
22		
23		
24		
25		
26		
27		
28		

DEMAND FOR JURY TRIAL 1 2 Femto-Sec requests a jury trial for all issues triable to a jury. 3 DATED: October 20, 2015 HAGENS BERMAN SOBOL SHAPIRO LLP 4 By: /s/ Philip Graves Philip Graves 5 philipg@hbsslaw.com 6 301 N. Lake Ave #203 7 Pasadena, CA 91101 Telephone: (213) 330-7147 8 9 Barbara Mahoney (pro hac vice) barbaram@hbsslaw.com 10 HAGENS BERMAN SOBOL SHAPIRO LLP 1918 8th Avenue, Suite 3300 11 Seattle, WA 98101 12 Telephone: (206) 623-7292 13 Facsimile: (206) 623-0594 14 Attorneys for Plaintiff FEMTÖ-SEC TECH, INC 15 16 17 18 19 20 21 22 23 24 25 26 27 28